Pipeline Strategy and Progress

Our pipeline strategy is to build a risk-controlled clinical-stage pipeline with an exclusive focus on novel or highly differentiated biologics. To achieve a delicate balance between exclusive positioning of highly innovative therapeutics and the related development risk, we have built a globally competitive biologics pipeline comprising a risk-controlled and “fast-to-market” China Portfolio and a transformational “fast-to-PoC (proof of concept)” Global Portfolio.

Copyright I-MAB Biopharma Co., Ltd. All rights reserved 2019 沪ICP备17007960号-2